Dose reduction is a feasible strategy in patients with plaque psoriasis who achieve sustained response with secukinumab: a retrospective, multicenter cohort study in daily practice setting.
Esteban DaudénElena EscarioLuisa Martos-CabreraSusana ArmestoEnrique Herrera-AcostaDavid VidalEva VilarrasaRaquel RiveraPablo de la CuevaAntonio MartorellFerran BallescaIsabel Belinchón-RomeroGregorio CarreteroLourdes RodríguezAlberto Romero-MatéJ Pujol-MontcusíLaura SalgadoAntonio Sahuquillo-TorralbaPablo Coto-SeguraOfelia BaniandrésR FeltesJosep Riera-MonroigJesus GarridoMar Llamas-VelascoPublished in: International journal of dermatology (2024)
Off-label SEC-DR strategy was used in patients with sustained response to standard dose regimen; this strategy showed long-term efficacy without compromising treatment survival or worsening the safety profile while also being cost saving.